| Withdrawn | Dynamic Whole Body PET/ MRI NCT04495959 | British Columbia Cancer Agency | — |
| Not Yet Recruiting | Cleaning the Biopsy Needle in TRUS Bx NCT06836271 | Hitit University | Phase 2 |
| Recruiting | Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors NCT06819215 | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Contribution of the VERITON-CT Camera in Prostate Bone Radiostereotaxy NCT06439784 | Centre Henri Becquerel | N/A |
| Recruiting | High-dose Brachytherapy Boost With Stereostatic Body Radiation Therapy to Intermediate or Higher Risk Prostate NCT05754580 | University of Nebraska | N/A |
| Recruiting | A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors NCT05740956 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 |
| Unknown | To Evaluate LUTS and Complications Between Indwelling Catheter and Temporary Prostatic Stent in Patients Under NCT05851521 | Lyx Institute | N/A |
| Recruiting | LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology NCT05184790 | University of Sydney | — |
| Completed | Fusion Versus Cognitive MRI Targeted Prostatic Biopsy NCT05969704 | Menoufia University | N/A |
| Withdrawn | Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC NCT05191017 | Nuvation Bio Inc. | Phase 1 / Phase 2 |
| Terminated | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid NCT05252390 | Nuvation Bio Inc. | Phase 1 |
| Unknown | 68Ga-labeled NY108 PET Imaging in Patients NCT05623878 | Affiliated Hospital of Jiangnan University | EARLY_Phase 1 |
| Active Not Recruiting | [68Ga]Ga-PSMA-11 PET/CT in the Assessment of High Risk and Recurrent Prostate Cancer NCT04484701 | British Columbia Cancer Agency | — |
| Unknown | Safety and Feasibility of Reversible Induction Strategy NCT04434963 | RenJi Hospital | — |
| Terminated | Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors NCT04541225 | Nuvation Bio Inc. | Phase 1 |
| Completed | Salvage HIFU for Local Recurrence in the Prostatic Bed After Prostatectomy and External Beam Radiation Therapy NCT04421781 | Hospices Civils de Lyon | — |
| Terminated | Quadratus Lumborum Block vs Transversus Abdominis Plane Block for Post-prostatectomy Analgesia NCT03606889 | Jagiellonian University | N/A |
| Completed | Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Base NCT03481816 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer NCT03354416 | National Cancer Institute (NCI) | — |
| Completed | Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy NCT03388619 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | Prostate Cancer Risk in Firefighters NCT03893123 | Oslo University Hospital | — |
| Enrolling By Invitation | 18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer NCT03181867 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer NCT03173924 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Clinical Trial to Examine Individual Pain Tolerance in the Use of Two Anesthetic Techniques to Perform Saturat NCT02909049 | Complexo Hospitalario Universitario de A Coruña | Phase 4 |
| Completed | Open Anterograde Radical Prostatectomy Compared to Open Retrograde Technique NCT02687308 | Rio de Janeiro State University | N/A |
| Completed | Optimizing the Effectiveness of Routine Post-treatment Surveillance in Prostate Cancer Survivors NCT02957357 | Alliance Foundation Trials, LLC. | — |
| Terminated | Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer NCT02349139 | Asana BioSciences | Phase 1 |
| Unknown | Stereotactic Body Radiotherapy for Stage I-III Prostate Cancer NCT02334579 | Swedish Medical Center | N/A |
| Completed | Prothrombotic Factors and Anaesthesia in Prostate Cancer NCT01998685 | Regina Elena Cancer Institute | N/A |
| Completed | Sipuleucel-T Manufacturing Demonstration Study NCT01477749 | Dendreon | Phase 2 |
| Completed | Early Urinary Continence After Radical Prostatectomy: Surgical Procedure and Anatomic Landmarks NCT04043637 | Consorci Sanitari Integral | — |
| Completed | Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT) NCT01284608 | AstraZeneca | — |
| Completed | North Carolina Prostate Cancer Comparative Effectiveness & Survivorship Study (NC ProCESS) NCT02564120 | UNC Lineberger Comprehensive Cancer Center | — |
| Unknown | To Evaluate the Technique and Effects of Separating the Prostate and Rectum With Hyaluronic Acid During Radiot NCT01787630 | Anders Widmark | Phase 2 / Phase 3 |
| Completed | Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Abl NCT00970203 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Effect of Adding Sufentanil to Epidural Ropivacaine on Perioperative Metabolic and Stress Responses in Combine NCT01086956 | Yonsei University | N/A |
| Completed | CyberKnife Radiosurgery for Organ-Confined Prostate Cancer: Homogenous Dose Distribution NCT00643994 | Accuray Incorporated | N/A |
| Completed | CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry NCT00643617 | Accuray Incorporated | N/A |
| Terminated | Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cance NCT00511576 | Mirati Therapeutics Inc. | Phase 1 |
| Completed | Quinacrine Treatment in Patients With Androgen-Independent Prostate Cancer NCT00417274 | Cleveland BioLabs | Phase 2 |
| Completed | Autologous Dendritic Cell Therapy for Hormone-Refractory Metastatic Prostate Cancer NCT01171729 | Samsung Medical Center | Phase 1 / Phase 2 |
| Completed | A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Che NCT00257478 | Astellas Pharma Inc | Phase 2 |